Rebecca A. Burrell, Sanjeev Kumar, Elena Provenzano, Cleopatra Pike, Alimu Dayimu, Stuart A. McIntosh, Vassilis Pitsinis, Polly King, Beatrix Elsberger, S. Govindarajulu, Lucy Satherley, Sirwan Hadad, Peter Schmid, Amit Agrawal, Bodiere Akpuluma, S. Bell, John R. Benson, C. Caldas, Danya Cheeseman, Igor Chernukhin, Parto Forouhi, Tulay Gulsen, Eleftheria Kleidi, Karen Pinilla, Wendi Qian, Jean Abraham, Jason S. Carroll, Richard D. Baird
Abstract The use of progestogens in breast cancer has been controversial. Recent preclinical studies have shown that ligand-bound progesterone receptor interacts directly with the estrogen receptor (ER) and reprograms ER transcriptional activity. Progestogen cotreatment enhances the antitumor activity of antiestrogen therapy in mouse xenografts. We report PIONEER, a 198-participant, three-arm, randomized phase 2b window-of-opportunity study for women with early-stage ER + breast cancer, which evaluated letrozole with or without megestrol at 40 mg or 160 mg daily. The primary endpoint was the change in tumor proliferation measured by Ki67 immunohistochemistry. Secondary and exploratory endpoints included a comparison of low versus higher dose of megestrol, safety, tolerability and biomarker subgroup analyses. The trial met its primary endpoint, with a greater reduction in proliferation seen when megestrol was added to letrozole. This effect was accompanied by reduced ER genomic binding at canonical binding sites in paired tumor biopsies, indicating reduced ER transcriptional activity. These results support further evaluation of low-dose megestrol, which has two mechanisms for potentially improving breast cancer outcomes in combination with standard antiestrogen therapy: alleviating hot flashes and thereby helping with treatment adherence, as well as a direct antiproliferative effect ( NCT03306472 ).